Mark Adamchak - 18 Sep 2024 Form 3 Insider Report for Bionano Genomics, Inc. (BNGO)

Role
Principal Accounting Officer
Signature
/s/ Jonathan V. Dixon, Attorney-in-Fact
Issuer symbol
BNGO
Transactions as of
18 Sep 2024
Net transactions value
$0
Form type
3
Filing time
30 Sep 2024, 16:51:22 UTC
Next filing
02 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BNGO Common Stock 16,471 18 Sep 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BNGO Stock Option (Right to Buy) 18 Sep 2024 Common Stock 1,200 $77.70 Direct F1
holding BNGO Stock Option (Right to Buy) 18 Sep 2024 Common Stock 584 $42.50 Direct F1
holding BNGO Stock Option (Right to Buy) 18 Sep 2024 Common Stock 753 $10.40 Direct F1
holding BNGO Stock Option (Right to Buy) 18 Sep 2024 Common Stock 4,999 $78.30 Direct F2
holding BNGO Stock Option (Right to Buy) 18 Sep 2024 Common Stock 8,750 $21.80 Direct F2
holding BNGO Stock Option (Right to Buy) 18 Sep 2024 Common Stock 6,899 $16.30 Direct F2
holding BNGO Stock Option (Right to Buy) 18 Sep 2024 Common Stock 8,750 $0.9300 Direct F2
holding BNGO Stock Option (Right to Buy) 18 Sep 2024 Common Stock 17,500 $0.9300 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option are fully vested and exercisable.
F2 The shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the grant date, such that the option shall be fully vested and exercisable on the four-year anniversary of the grant date, subject to continued service through each such applicable vesting date.
F3 100% of the shares subject to the option vest on the one-year anniversary of the grant date.